Sixteen-week-old mdx mice received a dietary supplement
with NR (400 mg/kg per day) for 12 weeks. (A) NR-treated
mdx mice exhibited increased α-dystrobrevin
(α-DB) (CD, 1.00 ± 0.35; NR, 1.61 ± 0.09) and
δ-sarcoglycan (δ-SG) (CD, 1.00 ± 0.15; NR, 2.24
± 0.43; P = 0.026) protein expression compared to HSP90
(Fig. 4D) as a loading control in
gastrocnemius extracts. NR attenuated mdx muscle damage as
evidenced through (B) Evans Blue staining of both TA muscle and
(C) sections of gastrocnemius and soleus muscles [red, Evans
Blue (EB); white, 4′,6-diamidino-2-phenylindole (DAPI)],
(D) quantified using ImageJ software (mdx, n = 6;
mdx NR, n = 12). (E) NR also
reduced basal plasma creatine kinase levels (mdx, n = 5;
mdx NR, n = 6). (F)
mdx mice treated with NR demonstrated an attenuation in the
percent loss of torque in quadriceps, after muscle damage induced by lengthening
contractions (mdx, n = 7; mdx NR,
n = 6). (G) Increases in the average minimal
Feret’s diameter (in micrometers) and cross-sectional area (CSA) (in
square micrometers) of tibialis anterior muscle fibers, indicating increases in
fiber size with NR treatment in mdx mice. These data were
acquired from images stained with DAPI and laminin [(H) shows a
representative image]. Quantification of images was performed with ImageJ
software (8 weeks of NR treatment, n = 5). (I)
Similarly, reduced CD45 staining was seen in diaphragms of mdx
mice treated with NR. (J) Reduced acetylation of p65
(NF-κB) protein after NR in quadriceps (CD, 1.00 ± 0.15; NR,
0.38 ± 0.16; P = 0.023; n = 3).
(K) FAPs expressing mesenchymal PDGFRα were decreased
in diaphragms of mdx mice treated with NR (n =
3). Also, reductions in the fibrosis of mdx diaphragms were
observed with less Picrosirius red staining in transverse muscle sections of
NR-treated mice. (L) PARylation intensity in skeletal muscle nuclei
of mdx mice is reduced with NR, as shown with
immunohistological staining of tibialis anterior muscle with PAR, CD45, and
laminin antibodies.